Masao Toyoda1, Hiroki Yokoyama2, Katsushige Abe3, Shuji Nakamura4, Daisuke Suzuki5. 1. Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara 259-1193, Kanagawa, Japan. Electronic address: m-toyoda@is.icc.u-tokai.ac.jp. 2. Jiyugaoka Medical Clinic Internal Medicine, Obihiro 080-0016, Hokkaido, Japan. 3. Abe Diabetes Clinic, Oita 870-0039, Oita, Japan. 4. Internal Medicine, Heiwadai Hospital, Miyazaki 880-0034, Miyazaki, Japan. 5. Suzuki Diabetes Clinic, Atsugi 243-0035, Kanagawa, Japan.
Abstract
AIM: In Japan, liraglutide is approved for use alone or in combination with sulfonylureas, and the approved maximum dosage is 0.9 mg/day. This restriction could limit the glucose-lowering effect of liraglutide in Japanese patients with type 2 diabetes mellitus (T2DM). This study was designed to identify predictors of response to liraglutide therapy at the approved dosage. METHODS: This observational retrospective study included 380 patients with T2DM who were treated with liraglutide alone or in combination with sulfonylureas at Diabetes Centers located in four geographically different areas of Japan. Binary logistic regression analysis was used to identify patient characteristics associated with discontinuation of liraglutide, while multiple regression and decision tree analyses were used to identify predictors of response to liraglutide therapy. RESULTS: Factors associated with discontinuation of liraglutide included high BMI, long duration of diabetes, and prior insulin therapy. Predictors of response to liraglutide therapy in patients who did not use insulin previously included previous use of few oral glucose-lowering agents and high baseline HbA1c level. CONCLUSION: The results suggest greater efficacy of liraglutide monotherapy or liraglutide-sulfonylurea combination therapy in patients with short duration of diabetes, non-insulin therapy, and low BMI and high HbA1c level at baseline.
AIM: In Japan, liraglutide is approved for use alone or in combination with sulfonylureas, and the approved maximum dosage is 0.9 mg/day. This restriction could limit the glucose-lowering effect of liraglutide in Japanese patients with type 2 diabetes mellitus (T2DM). This study was designed to identify predictors of response to liraglutide therapy at the approved dosage. METHODS: This observational retrospective study included 380 patients with T2DM who were treated with liraglutide alone or in combination with sulfonylureas at Diabetes Centers located in four geographically different areas of Japan. Binary logistic regression analysis was used to identify patient characteristics associated with discontinuation of liraglutide, while multiple regression and decision tree analyses were used to identify predictors of response to liraglutide therapy. RESULTS: Factors associated with discontinuation of liraglutide included high BMI, long duration of diabetes, and prior insulin therapy. Predictors of response to liraglutide therapy in patients who did not use insulin previously included previous use of few oral glucose-lowering agents and high baseline HbA1c level. CONCLUSION: The results suggest greater efficacy of liraglutide monotherapy or liraglutide-sulfonylurea combination therapy in patients with short duration of diabetes, non-insulin therapy, and low BMI and high HbA1c level at baseline.
Authors: Andrew McGovern; Zayd Tippu; William Hinton; Neil Munro; Martin Whyte; Simon de Lusignan Journal: BMJ Open Date: 2016-02-29 Impact factor: 2.692
Authors: Andrew McGovern; William Hinton; Silvio Calderara; Neil Munro; Martin Whyte; Simon de Lusignan Journal: Diabetes Ther Date: 2018-01-04 Impact factor: 2.945
Authors: Sofia Dahlqvist; Elsa Ahlén; Karin Filipsson; Thomas Gustafsson; Irl B Hirsch; Jaakko Tuomilehto; Henrik Imberg; Bo Ahrén; Stig Attvall; Marcus Lind Journal: BMJ Open Diabetes Res Care Date: 2018-02-24
Authors: N Simioni; C Berra; M Boemi; A C Bossi; R Candido; G Di Cianni; S Frontoni; S Genovese; P Ponzani; V Provenzano; G T Russo; L Sciangula; A Lapolla; C Bette; M C Rossi Journal: Acta Diabetol Date: 2018-03-12 Impact factor: 4.280